Initial biopsy outcome prediction - Head-to-head comparison of a logistic regression-based nomogram versus artificial neural network

被引:67
作者
Chun, Felix K. -H.
Graefen, Markus
Briganti, Alberto
Gallina, Andrea
Hopp, Julia
Kattan, Michael W.
Huland, Hartwig
Karakiewicz, Pierre I.
机构
[1] Univ Hamburg, Med Eppendorf, Prostate Canc Ctr, Martini Clin, D-20246 Hamburg, Germany
[2] Univ Hamburg, Dept Urol, D-20246 Hamburg, Germany
[3] Univ Montreal, Canc Prognost & Hlth Outcomes Unit, Montreal, PQ, Canada
[4] Cleveland Clin Fdn, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA
关键词
external validation; head-to-head comparison; nomogram; artificial neural network; initial prostate biopsy; prostate cancer;
D O I
10.1016/j.eururo.2006.07.021
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Nomograms and artificial neural networks (ANNs) represent alternative methodologic approaches to predict the probability of prostate cancer on initial biopsy. We hypothesized that, in a head-to-head comparison, one of the approaches might demonstrate better accuracy and performance characteristics than the other. Methods: A previously published nomogram, which relies on age, digital rectal examination, serum prostate-specific antigen (PSA), and percent-free PSA, and an ANN, which relies on the same predictors plus prostate volume, were applied to a cohort of 3980 men, who were subjected to multicore systematic prostate biopsy. The accuracy and the performance characteristics were compared between these two approaches. Results: The accuracy of the nomogram was 71% versus 67% for the ANN (p = 0.0001). Graphical exploration of the performance characteristics demonstrated virtually perfect predictions for the nomogram. Conversely, the ANN underestimated the observed rate of prostate cancer. Conclusions: A 4% increase in predictive accuracy implies that the use of the nomogram instead of the ANN will result in 40 additional patients who will be correctly classified between benign and cancer. (c) 2006 Published by Elsevier B.V. on behalf of European Association of Urology.
引用
收藏
页码:1236 / 1243
页数:8
相关论文
共 28 条
  • [1] [Anonymous], 2002, American Joint Committee on Cancer Staging Manual
  • [2] EAU guidelines on prostate cancer
    Aus, G
    Abbou, CC
    Bolla, M
    Heidenreich, A
    Schmid, HP
    van Poppel, H
    Wolff, J
    Zattoni, F
    [J]. EUROPEAN UROLOGY, 2005, 48 (04) : 546 - 551
  • [3] External validation is necessary in, prediction research: A clinical example
    Bleeker, SE
    Moll, HA
    Steyerberg, EW
    Donders, ART
    Derksen-Lubsen, G
    Grobbee, DE
    Moons, KGM
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2003, 56 (09) : 826 - 832
  • [4] Prostate biopsy and optimization of cancer yield
    Bostwick, DG
    Meiers, I
    [J]. EUROPEAN UROLOGY, 2006, 49 (03) : 415 - 417
  • [5] What information are urologists extracting from prostate needle biopsy reports and what do they need for clinical management of prostate cancer?
    Descazeaud, A
    Rubin, MA
    Allory, Y
    Burchardt, M
    Salomon, L
    Chopin, D
    Abbou, C
    de la Taille, A
    [J]. EUROPEAN UROLOGY, 2005, 48 (06) : 911 - 915
  • [6] Novel artificial neural network for early detection of prostate cancer
    Djavan, B
    Remzi, M
    Zlotta, A
    Seitz, C
    Snow, P
    Marberger, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (04) : 921 - 929
  • [7] Development of a nomogram that predicts the probability of a positive prostate biopsy in men with an abnormal digital rectal examination and a prostate-specific antigen between 0 and 4 ng/mL
    Eastham, JA
    May, R
    Robertson, JL
    Sartor, O
    Kattan, MW
    [J]. UROLOGY, 1999, 54 (04) : 709 - 713
  • [8] The potential impact of prostate volume in the planning of optimal number of cores in the systematic transperineal prostate biopsy
    Ficarra, V
    Novella, G
    Novara, G
    Galfano, A
    Pea, M
    Martignoni, G
    Artibani, W
    [J]. EUROPEAN UROLOGY, 2005, 48 (06) : 932 - 937
  • [9] Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels 10 ng/mL
    Garzotto, M
    Hudson, RG
    Peters, L
    Hsieh, YC
    Barrera, E
    Mori, M
    Beer, TM
    Klein, T
    [J]. CANCER, 2003, 98 (07) : 1417 - 1422
  • [10] Evidence suggesting PSA cutpoint of 2.5 ng/mL for prompting prostate biopsy: Review of 36,316 biopsies
    Gilbert, SM
    Cavallo, CB
    Kahane, H
    Lowe, FC
    [J]. UROLOGY, 2005, 65 (03) : 549 - 553